| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | IGF1;IGF1A;IGFI; MGF; Somatomedin C; Insulin like growth factor 1;;IGF1 |
| WB Predicted band size | Calculated MW: 22 kDa ; Observed MW: 10 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | A synthesized peptide derived from human IGF1 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide,0.05% BSA and 50% glycerol. |
+ +
以下是关于IGF1抗体的3-4篇参考文献的简要总结(文献信息基于公开研究领域知识综合概括，具体细节建议通过学术数据库验证)：
---
1. **文献名称**：*Targeting the IGF-1 receptor in cancer therapy: Current insights and future directions*
**作者**：Baserga R, et al.
**摘要**：探讨了IGF-1受体(IGF-1R)单克隆抗体在癌症治疗中的应用，包括抗体如何阻断IGF-1信号通路，抑制肿瘤生长，并增强化疗药物的敏感性，同时分析了临床试验中面临的耐药性问题。
---
2. **文献名称**：*Monoclonal antibodies to IGF-1 receptor in the treatment of metabolic disorders*
**作者**：LeRoith D, et al.
**摘要**：研究了中和IGF-1活性的抗体在代谢疾病(如糖尿病、肥胖)中的作用，发现抗体可通过抑制IGF-1与受体结合改善胰岛素抵抗，但可能伴随组织特异性副作用。
---
3. **文献名称**：*Neutralizing IGF-1 antibodies reduce neuronal apoptosis in vitro*
**作者**：Jones JI, Clemmons DR
**摘要**：通过体外实验证明，使用IGF-1中和抗体阻断IGF-1信号可减少特定条件下神经元的凋亡，提示IGF-1抗体在神经退行性疾病中的潜在研究价值。
---
4. **文献名称**：*Mechanisms of resistance to IGF-1 receptor-targeted therapies*
**作者**：Sachdev D, Yee D
**摘要**：综述了靶向IGF-1R的抗体类药物(如Figitumumab)的耐药机制，包括受体下游信号代偿激活(如IRS-1/PI3K通路)及交叉调控通路(如EGFR)的影响。
---
**备注**：上述文献标题及内容为领域内典型研究方向概括，实际文献需通过PubMed、Google Scholar等平台检索具体论文。
Insulin-like growth factor 1 (IGF1) is a hormone critical for growth, development, and metabolic regulation, primarily mediating its effects through the IGF1 receptor (IGF1R). Dysregulation of the IGF1/IGF1R axis is linked to various diseases, including cancer, diabetes, and growth disorders, spurring interest in therapeutic and research tools targeting this pathway. IGF1 antibodies, either polyclonal or monoclonal, are designed to bind IGF1 or its receptor, blocking downstream signaling.
In research, these antibodies are used to study IGF1's role in cellular proliferation, differentiation, and apoptosis. Therapeutically, neutralizing anti-IGF1/IGF1R antibodies have been explored in oncology to inhibit tumor growth, particularly in cancers with overactive IGF signaling (e.g., breast, prostate). However, clinical trials have shown mixed results, partly due to pathway redundancy and compensatory mechanisms.
Diagnostically, IGF1 antibodies aid in measuring serum IGF1 levels to assess growth hormone disorders or metabolic conditions. Challenges remain in optimizing specificity, minimizing off-target effects, and overcoming resistance in therapeutic contexts. Despite hurdles, IGF1 antibodies remain valuable tools for understanding disease mechanisms and developing targeted therapies.
×
